Dianabol steroids – selective beta1-blocker without intrinsic sympathomimetic activity. It has no membrane stabilizing (local anesthetic) activity. When topically applied dianabol steroids reduces both elevated and normal intraocular pressure due to decreased production of intraocular fluid.The onset of the hypotensive effect is usually observed after 30 minutes of use of the drug, and maximum decrease in IOP occurs in about 2 h. After a single impact on the installation ophthalmotonus maintained for 12 hours. dianabol steroids, compared with other beta-blockers, do not cause a decrease in blood flow in the optic nerve. dianabol steroids causes miosis, accommodation spasm, night blindness (unlike miotikov).
dianabol steroids highly lipophilic, resulting in good penetration through the cornea into the anterior chamber of the eye, the maximum concentration (C max ) is defined in the front chamber 20 minutes after the installation. When applied topically, systemic absorption is low, the plasma concentration is below the threshold (2 ng / ml) detected. Communication with plasma proteins – 50%. The half-life (T?) -. 14-22 hours excreted by the kidneys (15% unchanged). The permeability of the blood-brain barrier (BBB) and the placental barrier – low secretion of breast milk – small.
Pregnancy and lactation
Use of the drug during pregnancy and lactation (breastfeeding) is possible only when the intended benefits to the mother outweighs the potential risk to the fetus or child.
Dosing and Administration
Locally. 1 -2 eye drops into the conjunctival sac 2 times a day.
In some patients, the stabilization of intraocular pressure occurs within a few weeks, so it is recommended to control intraocular pressure within the first month of treatment.
If the desired level of intraocular pressure is not achieved during monotherapy Betoftanom should assign additional therapy.
Side effects: Local : short-term discomfort in the eyes after instillation, watery eyes; . in some cases – reduction in corneal sensitivity, redness of the eye, keratitis, photophobia, anisocoria, blurred vision, itching, a feeling of “dryness” of the eye, allergic reactions Systemic side effects are rare. On the part of the central nervous system (CNS) : dizziness, nausea, sonlivosg , insomnia, headache, depression, increased symptoms of myasthenia gravis. Since the cardiovascular system : bradycardia, cardiac conduction and heart failure. The respiratory system : dyspnea, bronchospasm, asthma, respiratory failure.
Currently, the cases of overdose were reported Betoftana.
When injected into an excess amount of the drug must be the eyes flush eyes with warm water.
In case of overdose beta1-blockers may occur: hypotension, bradycardia, congestive heart failure.
Treatment is symptomatic.
Interaction with other drugs
With simultaneous use of the drug Betoftan and adrenaline for oftalmologicheskogoprimeneniya solution in individual cases may develop mydriasis.
When using Betoftan drug in combination with drugs that deplete catecholamines (such as reserpine), may be observed amplification effects such as lowering blood pressure (BP) and bradycardia.
with the simultaneous use of the drug Betoftan and beta-blockers for griema inside, increases the risk of side effects (both local and systemic) due to the additive effect.
caution should be exercised when co-use of the drug Betoftan and adrenergic psychotropic drugs because of possible enhance their action. When concomitant administration of muscle relaxants and hypoglycemic agents strengthen their actions can be observed.
In a joint application with sympathomimetics -. Strengthening their vasoconstrictor effect
can be used in combination with other topical ophthalmic medications as needed. In this case, the interval between their use should be at least 10 minutes.
Betoftan contains the preservative benzalkonium chloride, which can be adsorbed soft contact lenses and have a damaging effect on the eye tissue. Therefore, patients wearing soft contact lenses, remove them before applying drops and set back no earlier than 20 minutes after instillation. To avoid contamination of the pipette, do not touch your eyes with instillation. Diabetes Mellitus: Beta-blockers should be used with caution in patients with a tendency to hypoglycemia, as these medications can mask the symptoms of acute hypoglycemia. Thyrotoxicosis: Beta-blockers may mask some of the symptoms of hyper-tireoza ( eg, tachycardia). In patients with suspected hyperthyroidism should not abruptly cancel beta-blockers, as this may cause increase in symptoms. Myasthenia : Beta-blockers can cause symptoms similar to those of myasthenia gravis (eg, diplopia, ptosis, generalized weakness). Surgery : Before elective surgery beta-blockers should be gradually (not simultaneously!) canceled 48 hours prior to general anesthesia, as during general anesthesia may reduce myocardial sensitivity to sympathetic stimulation, required for the heart. Pulmonary : caution should be exercised in the appointment of beta- blockers in patients with severely reduced function of the respiratory system. Despite the fact that clinical studies have shown no effect of dianabol steroids on respiratory function, should not exclude the possibility of hypersensitivity to the drug. The risk of an anaphylactic reaction : patients taking beta-blockers, may have a history of atopy or anaphylactic reactions. In the case of repeated reactions, such patients may not be sensitive to the usual doses of adrenaline necessary for relief of anaphylaxis. In installations drug can enter the systemic circulation. Thus, there may be side effects are the same as in the intravenous and parenteral administration of beta-blockers. Betoftan has minimal effect on blood pressure and heart rate. However, caution should be exercised in the appointment of his patients with atrioventricular block I degree, or heart failure. Treatment should be discontinued at the first signs of decompensation of the cardiovascular system. Patients who after the installation of the drug is temporarily reduced the clarity of vision, it is not recommended to engage in activities that require attention and response to his recovery.
Eye drops 0.5%.
In 5 ml of solution in a white polymer bottle-dropper indoor polymer cap with safety ring. One dropper bottle with instructions for use in a carton box.